Side Effects and Safety Information

Discover the safety profile of BENLYSTA and possible side effects.

This, however, is not all the safety information and does not replace talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about BENLYSTA?

Possible severe side effects of BENLYSTA:

Immunosuppressive agents, including BENLYSTA, can cause serious side effects. Some of these side effects may cause death. The following are serious adverse reactions that have occurred in patients receiving BENLYSTA:

 

  • Infections

    Infections could be serious, leading to hospitalization or death. Tell your doctor right away if you have any of the following symptoms of infection: fever, chills, pain or burning with urination, urinating often, coughing up mucus, or warm, red, or painful skin or sores on your body.

     

  • Allergic (hypersensitivity) reactions

    Serious allergic reactions can happen on the day of, or in the days after, receiving BENLYSTA and may cause death. Your doctor will watch you closely while you are receiving BENLYSTA given in a vein (intravenous infusion) and after your infusion for signs of a reaction. Allergic reactions can sometimes be delayed. Tell your doctor right away if you have any of the following symptoms of an allergic reaction following use of BENLYSTA: itching; swelling of the face, lips, mouth, tongue, or throat; trouble breathing; anxiousness; low blood pressure; dizziness or fainting; headache; nausea; or skin rash.

     

  • Mental health problems and suicide

    Symptoms of mental health problems can occur. Tell your doctor right away if you have any of the following symptoms: thoughts of suicide or dying, attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety, new or worse depression, acting on dangerous impulses, other unusual changes in your behavior or mood, or thoughts of hurting yourself or others.

BENLYSTA has been prescribed for more than 15 years by doctors for people with lupus.

Woman blowing out a butterfly-shaped candle on a purple cake with the letter B on it

BENLYSTA can cause serious side effects, including:

  • Progressive multifocal leukoencephalopathy (PML)

    PML is a serious and life-threatening brain infection. Your chance of getting PML may be higher if you are treated with medicines that weaken your immune system, including BENLYSTA. PML can result in death or severe disability. If you notice any new or worsening medical problems such as those below, tell your doctor right away: memory loss, trouble thinking, dizziness or loss of balance, difficulty talking or walking, or loss of vision.

     

  • Cancer

    BENLYSTA may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers.

The most common side effects of BENLYSTA include:

Nausea, diarrhea, fever, stuffy or runny nose and sore throat (nasopharyngitis), persistent cough (bronchitis), trouble sleeping (insomnia), leg or arm pain, depression, headache (migraine), and pain, redness, itching, or swelling at the site of injection (when given subcutaneously).

 

Please see the full Prescribing Information and Patient Information for BENLYSTA for more information, or ask your doctor. These are not all of the possible side effects of BENLYSTA. Call your doctor for medical advice about side effects. You may report side effects to the FDA by phone at 1-800-FDA-1088 or online at FDA.gov/medwatch. You may also report negative side effects to GSK at https://gsk.public.reportum.com or 1-888-825-5249. Your doctor can help determine if BENLYSTA is right for you.

Group of women sitting on and standing behind a purple couch with purple pillows and yellow B-shaped pillows

Safety profile of BENLYSTA from clinical trials

BENLYSTA has been studied in clinical trials with 7,000+ diverse patients over 11 years (4,000+ patients received BENLYSTA + common lupus medications while other patients received a placebo + common lupus medications).

 

  • Adults with lupus
  • Adults with lupus nephritis
  • Adults of Black race with lupus 
  • Children 5 years and older with lupus 
  • Post-marketing safety trial in adults with lupus 

 

BENLYSTA demonstrated a consistent safety profile after being studied in more clinical trials than any other lupus medicine or medicine for lupus nephritis, including the largest clinical trial in patients with lupus nephritis. BENLYSTA was studied in 8 different clinical trials that included diverse patient populations.

There are many things to think about when considering a new lupus medication

Your doctor can help you make an informed decision about the potential risks and benefits of lupus treatment based on your individual needs.

Dark-haired woman's face framed between two standing sets of books

Can I take BENLYSTA with my current medications?

You take BENLYSTA with your other lupus or lupus nephritis medicines. BENLYSTA is prescribed alongside other lupus medications, including corticosteroids (such as prednisone), antimalarials (such as Plaquenil®), and immunosuppressive agents (such as CellCept® or methotrexate). In clinical trials, BENLYSTA was administered with other drugs, such as antihypertensives, ACE inhibitors, statins, and NSAIDs.

Trademarks are property of their respective owners.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medications, vitamins, and herbal supplements. Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine.

Who shouldn’t take BENLYSTA?

Do not receive BENLYSTA if you are allergic to belimumab or any ingredients in BENLYSTA. See the end of the Medication Guide for a complete list of ingredients in BENLYSTA.

Before you receive BENLYSTA, tell your doctor about all of your medical conditions, including if you:

  • think you have an infection or have infections that keep coming back. You should not receive BENLYSTA if you have an infection unless your doctor tells you to. See “What is the most important information I should know about BENLYSTA?"

  • have or have had mental health problems such as depression or thoughts of suicide.

  • have recently received a vaccination or if you think you may need a vaccination. If you are receiving BENLYSTA, you should not receive live vaccines.

  • are allergic to other medicines.

  • are receiving other biologic medicines or monoclonal antibodies.

  • have or have had any type of cancer.

  • are pregnant or plan to become pregnant. It is not known if BENLYSTA will harm your unborn baby. You should talk to your doctor about whether to prevent pregnancy while on BENLYSTA. If you choose to prevent pregnancy, you should use an effective method of birth control while receiving BENLYSTA and for at least 4 months after the final dose of BENLYSTA.

    • Tell your doctor right away if you become pregnant during your treatment with BENLYSTA or if you think you may be pregnant.

    • If you become pregnant while receiving BENLYSTA, talk to your doctor about enrolling in the BENLYSTA Pregnancy Registry. You can enroll in this registry by calling 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/benlysta-belimumab/ . The purpose of this registry is to collect information about the health of you and your baby.

    • If you are breastfeeding or plan to breastfeed, you and your doctor should talk about whether or not you should receive BENLYSTA and breastfeed. It is not known if BENLYSTA passes into your breast milk.

Talk to your care team to see if BENLYSTA may be right for you

Approved Use & Safety Info

Approved Use

Important Safety Information

Approved Use

What is BENLYSTA?

BENLYSTA is a prescription medicine used to treat adults and children 5 years of age and older with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (LN) (lupus-related kidney inflammation) who are receiving other lupus medicines. It is not known if BENLYSTA is safe/effective in people with severe active central nervous system lupus.

 

It is not known if BENLYSTA is safe and effective for use in children less than 5 years of age.

 

It is not known if BENLYSTA, given under the skin (subcutaneously), is safe and effective for use in children who weigh less than 33 pounds (15 kilograms).

Important Safety Information

Do not use BENLYSTA if you are allergic to belimumab or any ingredients in BENLYSTA.

 

The most important information about BENLYSTA

 

Immunosuppressive agents, including BENLYSTA, can cause serious side effects. Some of these may cause death.

  • Infections: fever, chills, pain or burning with urination, urinating often, coughing up mucus, or warm, red, or painful skin or sores on your body. Infections could be serious, leading to hospitalization or death.
  • Allergic (hypersensitivity) reactions: itching, swelling of the face, lips, mouth, tongue, or throat, trouble breathing, anxiousness, low blood pressure, dizziness or fainting, headache, nausea, or skin rash. Serious allergic reactions can happen the day of, or in days after, receiving BENLYSTA and may cause death.
  • Mental health problems and suicide: thoughts of suicide or dying, attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety or depression, acting on dangerous impulses, other unusual changes in your behavior or mood, or thoughts of hurting yourself or others.

 

Before receiving BENLYSTA, discuss with your healthcare provider if you:

  • think you have an infection or have infections that keep coming back. Do not use BENLYSTA if you have an infection unless your healthcare provider tells you to.
  • have or have had mental health problems such as depression or thoughts of suicide.
  • have recently received or may need a vaccination. If you are receiving BENLYSTA, you should not receive live vaccines.
  • are taking any medicines, including prescription, over-the-counter, vitamins, and herbal supplements.
  • are allergic to other medicines.
  • are receiving other biologic medicines.  
  • have or have had any type of cancer.
  • have any other medical conditions.
  • are pregnant or plan to become pregnant. It is unknown if BENLYSTA will harm your unborn baby. Talk to your healthcare provider about whether to prevent pregnancy while on BENLYSTA. If you choose to prevent pregnancy, you should use an effective method of birth control for at least 4 months after the final dose of BENLYSTA.
  • become pregnant while receiving BENLYSTA, talk to your healthcare provider about enrolling in the BENLYSTA Pregnancy Registry. You can enroll in this registry by calling 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/benlysta-belimumab/.
  • are breastfeeding or plan to breastfeed. It is unknown if BENLYSTA passes into your breast milk.

 

Possible side effects of BENLYSTA

  • Progressive multifocal leukoencephalopathy (PML). PML is a serious and life-threatening brain infection. PML can result in death or severe disability. Tell your healthcare provider right away if you notice any new or worsening medical problems: memory loss, trouble thinking, dizziness or loss of balance, difficulty talking or walking, or loss of vision.
  • Cancer. Medicines that affect the immune system, including BENLYSTA, may increase your risk of certain cancers.

 

The most common side effects of BENLYSTA are nausea, diarrhea, fever, stuffy or runny nose and sore throat, persistent cough, trouble sleeping, leg or arm pain, depression, headache, and pain, redness, itching, or swelling at the site of injection (when given subcutaneously). These are not all the possible side effects of BENLYSTA. Call your doctor for medical advice about side effects.

 

Please see Prescribing Information and Medication Guide for BENLYSTA.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
GSK Help Center logo

Explore the GSK Help Center website to find customer service support and contact information.

Pay as little as zero dollars

Eligible commercially insured patients may pay as little as $0 for BENLYSTA, subject to program maximums.*

*Program annual maximums apply. Visit BenlystaCopayProgram.com for information about eligibility and full program terms and conditions.